Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

2.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

3.

Radiation therapy for patients with breast cancer

4.

Unified Neuro/Psych Residency Program: New Proposal.

5.

How access to specialized cancer centers affects glioblastoma outcomes


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot